We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A New York district judge has once again thrown out a whistleblower complaint alleging that Novartis offered doctors kickbacks to entice them to prescribe its multiple sclerosis blockbuster Gilenya (fingolimod). Read More
The investigational treatment also received Fast Track designation from the FDA in August for the treatment of patients with pulmonary sarcoidosis. Read More
New generic drug approvals in 2018, 2019 and 2020 yielded $53.3 billion in savings, according to a new FDA report that analyzed results from 2,400 approved new generic drug applications. Read More
The day a bench trial was slated to begin in Delaware federal court on Gilead’s five patent disputes with generic drug makers who were poised and ready to make copies of Gilead’s two HIV blockbuster drugs and its hepatitis B drug, the company announced that it had settled the disputes. Read More
Political pressure and internet-bred conspiracy theories have eroded one of the FDA’s prime functions — the communication of scientific truth, FDA Commissioner Robert Califf said at the annual meeting of the Regulatory Affairs Professional Society (RAPS) taking place in Phoenix this week. Read More
President Biden signed an executive order Monday authorizing a new initiative to help grow U.S. biomanufacturing, curtail dependence on foreign suppliers for critical supplies like active pharmaceutical ingredients (APIs) and establish and train a highly skilled workforce. Read More
There are currently no approved pharmaceutical treatments specifically indicated for the treatment of acute lower back pain, the company said. Read More